login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
IMUNON INC (IMNN) Stock News
USA
- NASDAQ:IMNN -
US15117N7012
-
Common Stock
4.72
USD
-0.13 (-2.68%)
Last: 10/27/2025, 8:00:02 PM
4.75
USD
+0.03 (+0.64%)
After Hours:
10/27/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IMNN Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Imunon, Inc.
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
8 days ago - By: Imunon, Inc.
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
11 days ago - By: Imunon, Inc.
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
12 days ago - By: Benzinga
- Mentions:
GALT
ADAP
PRME
GNPX
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
14 days ago - By: Imunon, Inc.
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
3 months ago - By: Benzinga
- Mentions:
AFG
CXDO
YUM
PACK
...
Earnings Scheduled For August 5, 2025
3 months ago - By: Stocktwits
- Mentions:
VXF
Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued
3 months ago - By: Imunon, Inc.
IMUNON Announces Reverse Stock Split
a month ago - By: Imunon, Inc.
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
a month ago - By: Imunon, Inc.
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
2 months ago - By: Imunon, Inc.
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2 months ago - By: Imunon, Inc.
IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
3 months ago - By: Imunon, Inc.
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
3 months ago - By: Imunon, Inc.
IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: Imunon, Inc.
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
3 months ago - By: Imunon, Inc.
IMUNON Announces Stock Dividend Boosting Shareholder Value
3 months ago - By: Imunon, Inc.
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
4 months ago - By: Imunon, Inc.
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
4 months ago - By: Imunon, Inc.
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
5 months ago - By: Virtual Investor Conferences
- Mentions:
NIKA
TIVC
ADIA
STSS
...
Life Sciences Investor Forum: Now Available for Online Viewing
5 months ago - By: Virtual Investor Conferences
- Mentions:
NIKA
TIVC
ADIA
STSS
...
Life Sciences Investor Forum Agenda Announced for June 11th-12th
5 months ago - By: Imunon, Inc.
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
5 months ago - By: Imunon, Inc.
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Please enable JavaScript to continue using this application.